News
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
Cars.com ( CAR) (upgraded to Overweight from Neutral): "There are signs of improvement in product development and adoption, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results